2020-04-27T09:59:47Z
2020-04-27T09:59:47Z
2019-11-04
2020-04-27T09:59:47Z
SETD1B is a component of a histone methyltransferase complex that specifically methylates Lys-4 of histone H3 (H3K4) and is responsible for the epigenetic control of chromatin structure and gene expression. De novo microdeletions encompassing this gene as well as de novo missense mutations were previously linked to syndromic intellectual disability (ID). Here, we identify a specific hypermethylation signature associated with loss of function mutations in the SETD1B gene which may be used as an epigenetic marker supporting the diagnosis of syndromic SETD1B-related diseases. We demonstrate the clinical utility of this unique epi-signature by reclassifying previously identified SETD1B VUS (variant of uncertain significance) in two patients.
Article
Published version
English
BioMed Central
Reproducció del document publicat a: https://doi.org/10.1186/s13148-019-0749-3
Clinical Epigenetics, 2019, vol. 11, p. 156
https://doi.org/10.1186/s13148-019-0749-3
info:eu-repo/grantAgreement/EC/FP7/223143/EU//TECHGENE
cc-by (c) Krzyzewska, I.M. et al., 2019
http://creativecommons.org/licenses/by/3.0/es